Purpose: To report a single-center study comparing drug-coated balloon (DCB) angioplasty vs directional atherectomy with antirestenotic therapy (DAART) for isolated lesions of the popliteal artery. Methods: Seventy-two patients were treated with either DCB angioplasty alone (n=31) or with DAART (n=41) for isolated popliteal artery stenotic disease between October 2009 and December 2015. The majority of patients presented with lifestyle-limiting claudication (74% vs 86%, respectively). Vessel calcification (29% vs 29%, respectively), mean lesion length (47 vs 42 mm, respectively), and number of runoff vessels were comparable between the groups. The primary outcome measure was primary patency; secondary outcomes were technical success (<30% residual stenosis or bailout stenting), secondary patency, and freedom from clinically driven target lesion revascularization (TLR). Results: The technical success rate following DCB was 84% vs 93% (p=0.24) after DAART. The 12-month primary patency rate was significantly higher in the DAART group (65% vs 82%; hazard ratio 2.64, 95% confidence interval 1.09 to 6.37, p=0.021), while freedom from TLR did not differ between the 2 treatment strategies (82% vs 94%, p=0.072). Secondary patency at 12 months was identical for both groups (96% vs 96%). Although not statistically significant, bailout stenting was more common after DCB angioplasty (16% vs 5% for DAART, p=0.13) and aneurysmal degeneration of the popliteal artery was seen more often after DAART (7% vs 0% for DCB alone, p=0.25). Popliteal artery injury was observed in 2 patients treated using DAART (5% vs 0% for DCB alone, p=0.5), whereas distal embolization rates were comparable between the groups (3% for DCB alone vs 5% for DAART, p=0.99).
Introduction
Despite the current advantages of endovascular therapy, its application in areas of high mechanical stress remains challenging. In case of popliteal artery disease, the mobility of the knee joint leads to additional dynamic forces within the vessel, which have been associated with accelerated restenosis and high rates of stent fractures and occlusions. 1, 2 Hence, the popliteal artery was long considered by many interventionists as a "no stenting" zone. However, the development of new-generation devices improved the results of stent therapy in this anatomical territory, but impaired arterial remodeling and interference with future surgical options are disadvantages. [2] [3] [4] [5] Additionally, in the absence of clear-cut solutions, in-stent restenosis (ISR) remains a challenging complication of infrainguinal peripheral artery disease (PAD) treatment. 6 The "leave nothing behind" strategies, namely, drugcoated balloon (DCB) angioplasty and combined directional atherectomy and antirestenotic therapy (DAART), can theoretically overcome the problems caused by the mobility of the knee joint. DCB angioplasty was found to be superior to plain angioplasty for femoropopliteal disease in numerous randomized control trials. 5 Moreover, a recently published single-arm study reported promising results of DAART for isolated popliteal disease. 7 Additionally, the DEFINITIVE AR trial suggested an added benefit for DAART in long and calcified femoropopliteal lesions compared to DCB angioplasty alone. 8 However, data concerning the efficacy of DCB angioplasty for isolated popliteal lesions are missing, and no study has compared the outcomes of these modalities in this anatomical region. The aim of this study was to evaluate the performance of DCB angioplasty and DAART for isolated popliteal artery lesions.
Methods

Study Design and Patient Population
Seventy-two symptomatic PAD patients were treated at a single center between October 2009 and December 2015 for isolated popliteal lesions with at least 1 patent (<50% stenosis) outflow artery to the ankle. Patients with tibial vessel lesions requiring treatment, the presence of ISR or bypass restenosis, acute limb ischemia, neoplastic disease, or clotting disorders were not included in the analysis. Superficial femoral artery (SFA) disease was not an exclusion criterion as long as the popliteal lesions were isolated and not a continuous femoropopliteal lesion. Nine patients in this time frame were treated with primary stent implantation, but because of the small number, they were excluded from the analysis. The study adhered to the Declaration of Helsinki, and all patients provided written inform consent for the procedure. Table 1 summarizes the patient and lesion characteristics at baseline. Fifty-eight (81%) patients presented with Rutherford category 3 claudication, 6 (8%) patients with ischemic rest pain (category 4), and 8 (11%) patients had tissue loss (category 5). The majority of lesions were de novo popliteal lesions in both groups. The mean nominal diameter of the popliteal artery was 6.0±1.0 mm, and the mean stenosis diameter was 1.2±1.1 mm.
Study Treatments
Patients underwent a thorough clinical examination at baseline and were started on acetylsalicylic acid (ASA; 100 mg/d). In the DCB angioplasty group, dilation with a standard uncoated balloon inflated to ~1 mm less than the nominal diameter was performed in all cases to decrease the risk of drug loss. Adjunctive DCB therapy was then In the DAART patients, all procedures were performed with a distal protection device (SpiderFX embolic protection device; Medtronic). The filter was placed proximal to the origin of the anterior tibial artery, and the device size was slightly larger than the vessel diameter. In cases of distal popliteal artery disease, the device was positioned in the tibioperoneal trunk when all tibial vessels were patent or in the most prominent tibial vessel in cases of tibioperoneal disease.
Directional atherectomy was applied to reduce the plaque burden of the target lesion at least 50%. Four different devices were used: TurboHawk atherectomy catheter (Medtronic), the SilverHawk peripheral plaque excision system (Medtronic), the Pantheris optical coherence tomography atherectomy catheter (Avinger Inc, Redwood City, CA, USA), and the HawkOne atherectomy device (Medtronic).
Adjunctive DCB therapy as described above was applied in all cases, but conventional balloon angioplasty was not performed before DCB use. The goal of DAART was to achieve a <30% residual stenosis by visual estimation. Again, flow-limiting dissections were treated with prolonged angioplasty using an uncoated balloon, and bailout stenting was indicated only in cases of persistent major dissection or recoil after prolonged vessel dilation. The choice of paclitaxel-coated balloon and debulking device was at the discretion of the treating interventionist.
Dual antiplatelet therapy with ASA (100 mg/d) and clopidogrel (75 mg/d) was prescribed for 8 weeks, followed by ASA or clopidogrel monotherapy. Patients previously taking warfarin were maintained on the anticoagulant with an additional single antiplatelet agent for 8 weeks after the procedure and warfarin monotherapy thereafter. Triple therapy (ASA, clopidogrel, warfarin) was not favored.
Follow-up examinations were scheduled at 6 and 12 months after the initial procedure and annually thereafter or in case of clinical worsening. The patency of the treated vessels was assessed by duplex ultrasound at each followup unless symptoms warranted angiography.
Endpoints and Definitions
The main outcome measure of this study was primary patency, defined as freedom from significant restenosis or occlusion based on duplex ultrasound evaluation and no reintervention. Secondary outcomes were technical success, secondary patency, and freedom from clinically-driven target lesion revascularization (TLR). Technical success was defined as residual stenosis <30% in the absence of arterial perforation of the treated segment. Secondary patency was defined as restored flow in the treated segment after occlusion or restenosis. Significant restenosis was indicated by a >2.0 peak systolic velocity ratio calculated as the peak systolic flow velocity in the lesion divided by the peak systolic velocity 1 cm proximal to the lesion. Bailout stenting was considered loss of primary patency and associated with technical failure.
The degree of calcification was graded on the basis of arterial wall calcium deposits. Mild calcification referred to calcifications <1 cm long on one side of the lumen on the preoperative angiogram, whereas moderate calcification was the presence of deposits on both sides of the lumen over a length <1 cm. Severe calcification was the presence of radiopacities on both sides of the arterial wall over a length >1 cm. 9 The popliteal artery was divided in 3 anatomical segments: P1, from the intercondylar fossa to the proximal edge of patella; P2, between the proximal part of the patella and the center of the knee joint space; and P3, between the knee joint space and the origin of the anterior tibial artery.
Statistical Analysis
Continuous variables are presented as means ± standard deviation, while categorical data are given as the counts. Continuous numerical variables were compared by means of a paired Student t test. Cumulative primary and secondary patency rates, as well as freedom from TLR, were estimated using the Kaplan-Meier method. Hazard ratios (HR) are given with the 95% confidence interval (CI). The threshold of statistical significance was p<0.05. Analyses were performed using MedCalc Statistical Software (version 12.4.0.0; MedCalc Software, Ostend, Belgium).
Results
There was no statistically significant difference between the 2 groups concerning the clinical status at presentation based on the Rutherford category (p=0.44). Patients undergoing DCB angioplasty alone were older (mean age 72 vs 68 years, p=0.03), while men were predominant in the DAART group (71% vs 29% for DCB alone, p<0.001). Popliteal artery occlusion was present in 36% of the DCB only patients vs 44% (p=0.47) of the DAART patients. The mean lesion length was similar for both groups (47±24 vs 42±24 mm, respectively; p=0.42). Vessel calcification (29% vs 29%), as well as calcification severity, were comparable between the groups.
Initial Outcomes
Technical success (Table 2 ) in the DCB group was 84% vs 93% in the DAART group (p=0.24). The mean contrast volume was higher among patients treated with DAART (160±62 vs 121±45 mL for DCB alone, p=0.009), while there was no difference in the median radiation dose area product. The mean lumen diameter following atherectomy was 4.6±1.1 mm (luminal gain 56%±20%), and the vessel diameter after DCB angioplasty was 5.5±1.1 mm (luminal gain 70%±18%). No statistically significant difference was observed regarding the use of the different DCB devices. Despite a greater need for adjunctive stenting (bailout) in the DCB only patients, the difference was not statistically significant (16% vs 5%, p=0.13).
Complications
Final angiography revealed a popliteal artery injury in 1 DAART patient following TurboHawk atherectomy; the defect was treated by prolonged dilation with an uncoated balloon followed by DCB angioplasty. Distal embolization, which was also comparable between the groups (1 in the DCB only group vs 2 in the DAART patients), was treated by endovascular means (prolonged balloon dilation or endovascular aspiration/ thrombectomy).
Additionally, a female patient complained of painful edema of the popliteal fossa 24 hours after DAART. Computed tomography angiography revealed a perforation of the popliteal artery, which was treated surgically. Thus, the overall rate of popliteal artery injury was 5% post DAART (n=2). Perforation was not observed after DCB angioplasty, but the difference did not reach statistical significance (p=0.50).
Puncture site complications consisted of 3 false aneurysms requiring surgical treatment, 1 following DCB angioplasty and 2 after DAART. Two hematomas without evidence of false aneurysm formation (1 in each group) were treated conservatively.
Outcomes in Follow-up
The mean follow-up was 12 months (range 0.9-48.3) in the DCB group and 10 months (range 1-58.3) in the DAART group. No amputations were performed. One DAART patient died of unknown causes (overall mortality 1.3%). The 82% 12-month primary patency (Figure 1 ) in the DAART group was higher than in patients treated with DCB angioplasty (65%; HR 2.64, 95% CI 1.09 to 6.37, p=0.021). The 12-month freedom from TLR was comparable between the groups (82% vs 94%, respectively; p=0.07). Secondary patency was the same between the 2 modalities at 96%. The majority of patients in both groups remained asymptomatic (Rutherford category 0-1) in follow-up (Figure 2) .
A clinically-driven TLR was performed in 8 patients who had restenosis treated initially by DCB angioplasty. Three patients were treated with DAART, 2 with DCB angioplasty, and 2 with a nitinol interwoven stent (Supera; Abbott Vascular, Santa Clara, CA, USA). The last patient underwent surgical conversion.
In the DAART group, 5 reinterventions were performed. DAART was again the treatment of choice in 3 patients, a Supera stent was used to treat a popliteal reocclusion, and a stent-graft was deployed to treat aneurysmal degeneration of the popliteal artery.
Popliteal aneurysm formation was observed in 3 (7%) patients treated by DAART vs none in the DCB group (p=0.25). One patient with a 2.5-cm popliteal artery diameter was treated with a Viabahn stent-graft (W. L. Gore & Associates, Flagstaff, AZ, USA) in the degenerated segment ( Figure 3) . The other 2 patients remain under strict surveillance; the aneurysm diameters are <2 cm, and there are no signs of peripheral embolization. Notably, in the completion angiograms of all 3 cases, there was no sign of vessel injury or aneurysm formation.
Discussion
Isolated lesions of the popliteal artery represent a rare manifestation of PAD. Typically, popliteal and SFA lesions are studied together as femoropopliteal disease. However, the axial shortening, elongation, and bending to which both vessels are exposed vary according to the specific anatomical location within this vascular bed. 10 Hence, the unique anatomical environment and the high mechanical stress at the popliteal fossa make a separate analysis of popliteal artery disease more meaningful. In this cohort, DAART achieved better primary patency compared with patients treated by DCB alone, but both modalities showed excellent 12-month secondary patency and no statistically significant differences in TLR, adjunctive stent therapy, or aneurysmal degeneration.
In the pilot DEFINITIVE AR randomized trial, which compared the performance of DAART to DCB alone in femoropopliteal disease, there was a clear trend to better 12-month angiographic patency in favor of DAART (82.4% vs 71.8%), though it did not reach statistical significance. 8 In a single-center study, DAART was associated with higher 12-month primary patency over combination therapy with directional atherectomy and plain angioplasty for restenotic lesions. 11 Additionally, Cioppa et al 12 reported promising 1-year results following DAART for heavily calcified femoropopliteal lesions. It is likely that vessel preparation prior to DCB angioplasty leads to better paclitaxel penetration into the arterial wall and improved drug uptake. Moreover, the antiproliferative treatment minimizes the local inflammation caused by the rather aggressive mechanical plaque excision and, consequently, the risk for excessive neointima development. 13 There are 2 main concerns about the use of DCB in the peripheral vascular bed: the high risk for dissections with the consequent increased need for adjunctive stent therapy and, secondly, the poorer outcomes of DCB in calcified lesions. 6, 14 In regard to dissections and provisional stent therapy, the reported stent rates vary among the published studies. 6 Notably, the 7.3% bailout stent rate in the IN.PACT SFA trial 15 was far lower than the 46.8% provisional stent use reported in the chronic occlusion subgroup of the IN.PACT global registry. 16 In our cohort, 16% of the lesions treated with DCB alone required an adjunctive stent. Interestingly, in a subgroup analysis of the THUNDER trial, 17 dissections following DCB angioplasty were not associated with poorer outcomes even without stent placement, suggesting that a less aggressive approach could be equally effective. Nonetheless, the main aim of "leave nothing behind" therapies is to avoid stent implantation in an arterial segment exposed to mechanical stress. Concerning calcified lesions, Tepe et al 14 observed higher rates of late lumen loss following DCB angioplasty among calcified lesions and suggested that vessel preparation with debulking devices could be beneficial prior to antiproliferative treatment.
On the other hand, aneurysmal degeneration of the popliteal artery limited the performance of DAART in this cohort. Aneurysm formation has been reported after directional atherectomy or DCB angioplasty in the femoropopliteal vessels, 18, 19 as well as after drug-eluting stent placement in the coronary vessels. 20 However, the reported rates were significantly lower than the 7% observed in our study. The overall 30-day aneurysm formation rate was 0.5% in the DEFINITVE LE trial 18 and 0.6% in the TALON registry 21 ; however, no information was available in either study concerning degeneration of the treated vessels in the mid and long term.
A possible explanation for this aneurysm formation is a synergic action of paclitaxel and directional atherectomy. Minor injuries of the arterial wall during plaque excision could increase the toxicity of paclitaxel. In any case, avoiding deep injury to the adventitial layer during directional atherectomy remains crucial. 22 Hopefully, devices with optical coherence tomography could minimize the risk of vessel injury. Other possible limitations of DAART are the prolonged procedure time as a result of the many catheter reintroductions, the necessity of repeated angiograms and increased volume of contrast agent, the need of larger sheaths, and the high costs.
Plain angioplasty, cryoplasty, directional atherectomy, and stent therapy have also been proposed for the treatment of isolated popliteal artery lesions. In the COLD trial, 23 cryoplasty application was not associated with better outcomes than plain angioplasty. In a single-center study, directional atherectomy reduced the need for stent deployment compared with plain angioplasty; however, this did not translate to superior patency or TLR rates. 24 In the DEFINITVE LE trial, 18 the primary patency of popliteal lesions was 74%, but a severely calcified lesion was an exclusion criterion of this study. In contrast, a randomized trial showed that stent placement for isolated popliteal artery lesions was superior to angioplasty alone, despite a reported stent fracture rate of 4.6%. Interestingly, there was no correlation in this trial between stent fractures and vessel patency. 25 New-generation devices with increased flexibility and radial force have been linked to improved patency and reduced need for reinterventions. The reported 1-year primary patency rates of the Supera stent in the popliteal artery ranged between 68.4% and 88%, while the observed rate with the popliteal TIGRIS stents (W. L. Gore & Associates) at 12 months was 69.5%. [2] [3] [4] 26, 27 However, optimal deployment of the Supera stent remains crucial as stent elongation or intussusception is associated with loss of radial strength and higher rates of restenosis. 1, 28 Up to now there has been no clear solution concerning ISR, while popliteal stent occlusion is associated with loss of a bypass target. 6, 29 In our opinion, stent therapy with dedicated devices remains a viable treatment option, especially in severely calcified lesions, in elderly fragile patients, and in the settings of chronic kidney disease or long combined SFA/popliteal lesions (Figure 4 ).
Limitations
The lack of randomization, despite the comparable baseline characteristics of both groups, is a limitation of this singlecenter study. The underrepresentation of female patients in the DAART group could potentially affect the reported outcomes, although the influence of gender in endovascular therapy is still unclear. 30 Additionally, isolated popliteal lesions are rather rare; thus, the volume of patients studied is moderate.
Conclusion
In this nonrandomized, single-center study evaluating the performance of "leave nothing behind" therapies for isolated popliteal artery lesions, DAART was associated with a higher primary patency rate than DCB angioplasty alone. Nonetheless, both modalities showed an exceptional overall patency, offering an alternative endovascular approach in this region of high mechanical stress. Aneurysm formation and increased need for bailout stenting remain drawbacks of DAART and DCB angioplasty, respectively.
